AI Terminal
MaaT Pharma
Registration Form • Apr 14, 2025
1494_iss_2025-04-14_f3943b3b-fa6f-4ec1-b866-b794494f5073.pdf
Registration Form
Open in ViewerOpens in native device viewer
Availability of MaaT Pharma's 2024 Universal Registration Document (URD)
Lyon, France, April 14, 2025 – 6:00 pm CET – MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, announces that the French version of its 2024 Universal Registration Document was filed with the French Financial Markets Authority (Autorité des marchés financiers – AMF) on April 11, 2025, under number D.25-0249.
The 2024 Universal Registration Document includes the following documents:
- The annual financial report for the fiscal year ended December 31, 2024, including the Board of Directors' Corporate Governance Report;
- The auditors' reports and information related to their fees,
- Information on the Company's share buyback program.
The 2024 Universal Registration Document is available on the Company's website, in the 'Investors' section under "Regulated Information", as well as on the AMF website.
About MaaT Pharma
MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France. As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021.
Contacts
MaaT Pharma – Investor Relations Guilhaume DEBROAS, Ph.D. Head of Investor Relations +33 6 16 48 92 50 [email protected]
Rx Communications Group – U.S. Investor Relations Michael Miller Managing Director +1-917-633-6086 [email protected]
MaaT Pharma – Media Relations Pauline RICHAUD Senior PR & Corporate Communications Manager +33 6 14 06 45 92 [email protected]
Catalytic Agency – U.S. Media Relations Heather Shea Media relations for MaaT Pharma +1 617-286-2013 [email protected]